Hereditary Angioedema Market Expected to Experience Major Growth by 2034, According to DelveInsight | KalVista Pharma, Intellia Therapeutics, BioMarin Pharma, CSL Behring, Ionis Pharma

The Key Hereditary Angioedema Companies in the market include - Ionis Pharmaceuticals, Astria Therapeutics, KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, CSL Behring, Shire, and others.

DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hereditary Angioedema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Angioedema Market Forecast [https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Hereditary Angioedema Market Report:

*
The Hereditary Angioedema market size was valued approximately ~USD 3000 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
On November 4, 2024, Ionis Pharmaceuticals, Inc. announced that the U.S. FDA has accepted the New Drug Application (NDA) for donidalorsen, an experimental RNA-targeted therapy designed to prevent hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older.

*
In August 2024, Astria Therapeutics announced that it has chosen Ypsomed as its partner to collaborate on the development of an autoinjector for STAR-0215.

*
In June 2024, KalVista has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the review of sebetralstat, an innovative oral plasma kallikrein inhibitor for treating HAE attacks in adults and pediatric patients aged 12 and older.

*
In May 2024, Ionis Pharmaceuticals announced favorable outcomes from the Phase III OASIS-HAE and OASISplus studies of donidalorsen for hereditary angioedema (HAE). The studies demonstrated substantial and lasting reductions in monthly HAE attack rates, with more than 90% improvement after one year of treatment, regardless of whether the drug was administered monthly or bi-monthly. The results will be shared at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Valencia and published in The New England Journal of Medicine.

*
The United States holds the largest market size for Hereditary Angioedema, estimated at around USD 2,000 million in 2023, with expectations for growth during the forecast period.

*
Among the EU4 and the UK, France has the largest Hereditary Angioedema market size, approximately USD 100 million in 2023.

*
Hereditary angioedema (HAE) is commonly believed to affect women more than men, with around 65% of cases occurring in females.

*
Currently, three categories of Hereditary Angioedema medications-C1-INHs, 17 alpha-alkylated androgens, and antifibrinolytics-are utilized for the long-term prevention of HAE type 1 and 2.

*
The diagnosed prevalent population of HAE in the United States was estimated to be approximately 7,000 cases in 2023.

*
Type I Hereditary Angioedema (HAE) represented the largest share of diagnosed cases in the US, with approximately 5,500 cases in 2023.

*
Analysts estimated that approximately 1,000 cases were diagnosed in the age group of 17 to under 65 years in 2023.

*
Key Hereditary Angioedema Companies: Ionis Pharmaceuticals, Astria Therapeutics, KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, CSL Behring, Shire, and others

*
Key Hereditary Angioedema Therapies: Donidalorsen (IONIS-PKK-LRx), Navenibart (STAR-0215), KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others

*
The Hereditary Angioedema epidemiology based on gender analyzed that the diagnosed prevalent cases of Hereditary Angioedema in the 7MM varied according to gender, with prevalent cases higher in females than males

*
The Hereditary Angioedema market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Angioedema pipeline products will significantly revolutionize the Hereditary Angioedema market dynamics.

Hereditary Angioedema Overview

Hereditary Angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of swelling (angioedema) in various parts of the body, including the face, limbs, abdomen, and airways. The condition is caused by a deficiency or dysfunction of a protein called C1 inhibitor, which helps regulate inflammation. HAE attacks can be triggered by stress, trauma, or infections, and may result in painful swelling and potential life-threatening complications if the airway becomes involved. Treatment options include medications to prevent or treat attacks, such as C1 inhibitor replacement therapies, bradykinin receptor antagonists, and other targeted therapies.

Get a Free sample for the Hereditary Angioedema Market Report:

https://www.delveinsight.com/report-store/hereditary-angioedema-market [https://www.delveinsight.com/report-store/hereditary-angioedema-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hereditary Angioedema Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hereditary Angioedema Epidemiology Segmentation:

The Hereditary Angioedema market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Hereditary Angioedema

*
Prevalent Cases of Hereditary Angioedema by severity

*
Gender-specific Prevalence of Hereditary Angioedema

*
Diagnosed Cases of Episodic and Chronic Hereditary Angioedema

Download the report to understand which factors are driving Hereditary Angioedema epidemiology trends @ Hereditary Angioedema Epidemiology Forecast [https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hereditary Angioedema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched during the study period. The analysis covers Hereditary Angioedema market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hereditary Angioedema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hereditary Angioedema Therapies and Key Companies

*
Donidalorsen (IONIS-PKK-LRx): Ionis Pharmaceuticals

*
Navenibart (STAR-0215): Astria Therapeutics

*
KVD900: KalVista Pharmaceuticals

*
NTLA-2002: Intellia Therapeutics

*
BMN 331: BioMarin Pharmaceutical

*
Garadacimab: CSL Behring

*
Donidalorse: Ionis Pharmaceuticals

*
STAR-0215: Astria Therapeutics

*
PHA121: Pharvaris Netherlands B.V

*
NTLA-2002: Intellia Therapeutics

*
TAK-743: Takeda

*
KVD900: KalVista Pharmaceuticals

*
CSL312: CSL Behring

*
Lanadelumab: Shire

Discover more about therapies set to grab major Hereditary Angioedema market share @ Hereditary Angioedema Treatment Market [https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hereditary Angioedema Market Strengths

*
Increasing identification of a novel genetic mutation in various regions warranting further focus on the types and associated pathophysiology, including recognition of hormonal changes

Hereditary Angioedema Market Opportunities

*
Proliferating demand for therapies with improved patient compliance, fewer side effects, improved resistance profile, and long-acting therapies

Scope of the Hereditary Angioedema Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Hereditary Angioedema Companies: Ionis Pharmaceuticals, Astria Therapeutics, KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, CSL Behring, Shire, and others

*
Key Hereditary Angioedema Therapies: Donidalorsen (IONIS-PKK-LRx), Navenibart (STAR-0215), KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others

*
Hereditary Angioedema Therapeutic Assessment: Hereditary Angioedema current marketed and Hereditary Angioedema emerging therapies

*
Hereditary Angioedema Market Dynamics: Hereditary Angioedema market drivers and Hereditary Angioedema market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Hereditary Angioedema Unmet Needs, KOL's views, Analyst's views, Hereditary Angioedema Market Access and Reimbursement

To know more about Hereditary Angioedema companies working in the treatment market, visit @ Hereditary Angioedema Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hereditary Angioedema Market Report Introduction

2. Executive Summary for Hereditary Angioedema

3. SWOT analysis of Hereditary Angioedema

4. Hereditary Angioedema Patient Share (%) Overview at a Glance

5. Hereditary Angioedema Market Overview at a Glance

6. Hereditary Angioedema Disease Background and Overview

7. Hereditary Angioedema Epidemiology and Patient Population

8. Country-Specific Patient Population of Hereditary Angioedema

9. Hereditary Angioedema Current Treatment and Medical Practices

10. Hereditary Angioedema Unmet Needs

11. Hereditary Angioedema Emerging Therapies

12. Hereditary Angioedema Market Outlook

13. Country-Wise Hereditary Angioedema Market Analysis (2020-2034)

14. Hereditary Angioedema Market Access and Reimbursement of Therapies

15. Hereditary Angioedema Market Drivers

16. Hereditary Angioedema Market Barriers

17. Hereditary Angioedema Appendix

18. Hereditary Angioedema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hereditary-angioedema-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-kalvista-pharma-intellia-therapeutics-biomarin-pharma-csl-behring-ionis-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.